AN2 Therapeutics
ANTX
38 hedge funds and large institutions have $19.5M invested in AN2 Therapeutics in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 5 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0% more funds holding
Funds holding: 38 → 38 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.98% less ownership
Funds ownership: 48.63% → 47.65% (-0.98%)
3% less capital invested
Capital invested by funds: $20.1M → $19.5M (-$546K)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$865K |
| 2 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$81K |
| 3 |
AC
Aldebaran Capital
Carmel,
Indiana
|
+$79.2K |
| 4 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$62.9K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$32.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$271K |
| 2 |
Renaissance Technologies
New York
|
-$266K |
| 3 |
Millennium Management
New York
|
-$201K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$129K |
| 5 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$115K |
ANTX Hedge Fund Activity: Q1 2025 in Review
38 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q1 2025, worth a combined $19.5M — down 2.7% from $20.1M a quarter earlier.
Fund positioning in ANTX was balanced in Q1 2025: 5 funds opened new positions, 5 closed out, 8 added to existing stakes and 11 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $865K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $271K sold.
- 38 institutional investors held AN2 Therapeutics (ANTX) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $19.5M of AN2 Therapeutics stock for Q1 2025, down 2.7% quarter-over-quarter.
- 5 funds opened new AN2 Therapeutics positions in Q1 2025 and 5 closed out, a net change of 0 holders.
- The largest AN2 Therapeutics buyer in Q1 2025 was Adage Capital Partners, an estimated $865K added.
- The largest AN2 Therapeutics seller in Q1 2025 was Stonepine Capital Management, an estimated $271K sold.
Based on aggregated 13F filings for Q1 2025.